NCT04155840View on ClinicalTrials.gov

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 31, 2020

Primary Completion Date

March 16, 2021

Study Completion Date

March 16, 2021

Conditions
Lymphoid LeukemiaNon-Hodgkin's LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

Copanlisib

Given IV

BIOLOGICAL

Rituximab

Given IV

DRUG

Bendamustine

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University of Washington

OTHER

NCT04155840 - Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Biotech Hunter | Biotech Hunter